Two-year follow-up of ranibizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy

Rei Nemoto,1,2 Masahiro Miura,1,2 Takuya Iwasaki,1,2 Hiroshi Goto21Department of Ophthalmology, Tokyo Medical University, Ibaraki Medical Center, Ami, Ibaraki, Japan; 2Department of Ophthalmology, Tokyo Medical University, Nishi-Shinjuku, Tokyo, JapanPurpose: We evaluated the 2-year efficacy of comb...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nemoto R, Miura M, Iwasaki T, Goto H
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/5a9a36226e494f9d90526e06c51cd2a6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5a9a36226e494f9d90526e06c51cd2a6
record_format	dspace
spelling	oai:doaj.org-article:5a9a36226e494f9d90526e06c51cd2a62021-12-02T09:07:11ZTwo-year follow-up of ranibizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy1177-54671177-5483https://doaj.org/article/5a9a36226e494f9d90526e06c51cd2a62012-10-01T00:00:00Zhttp://www.dovepress.com/two-year-follow-up-of-ranibizumab-combined-with-photodynamic-therapy-f-a11213https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Rei Nemoto,1,2 Masahiro Miura,1,2 Takuya Iwasaki,1,2 Hiroshi Goto21Department of Ophthalmology, Tokyo Medical University, Ibaraki Medical Center, Ami, Ibaraki, Japan; 2Department of Ophthalmology, Tokyo Medical University, Nishi-Shinjuku, Tokyo, JapanPurpose: We evaluated the 2-year efficacy of combined intravitreal ranibizumab (IVR) treatment and photodynamic therapy (PDT) for treatment-na&iuml;ve polypoidal choroidal vasculopathy (PCV).Patients and methods: Twenty-two eyes of 22 Japanese patients with treatment-na&iuml;ve PCV were prospectively recruited. All eyes had angiographic features of PCV according to indocyanine green angiography. The initial combination treatment regimen included a session of PDT with IVR. A total of three consecutive IVR treatments were given at 4-week intervals. Eyes were retreated with IVR or PDT at specific times. We evaluated the mean visual acuity and mean central retinal thickness (CRT) at 3, 6, 9, 12, 18, and 24 months after initial treatment.Results: At month 9, visual acuity had improved by 5.7 letters (P = 0.10). Subsequently, mean visual acuity gradually decreased, and the difference from baseline was diminished to 2.9 letters at 24 months (P = 0.43). Mean CRT was significantly decreased from baseline over the 24-month follow-up (P &lt; 0.05).Conclusion: With PDT combined with IVR for PCV, visual acuity improved during year 1, but the benefit decreased in year 2.Keywords: photodynamic therapy, polypoidal choroidal vasculopathy, ranibizumabNemoto RMiura MIwasaki TGoto HDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2012, Iss default, Pp 1633-1638 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Nemoto R Miura M Iwasaki T Goto H Two-year follow-up of ranibizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy
description	Rei Nemoto,1,2 Masahiro Miura,1,2 Takuya Iwasaki,1,2 Hiroshi Goto21Department of Ophthalmology, Tokyo Medical University, Ibaraki Medical Center, Ami, Ibaraki, Japan; 2Department of Ophthalmology, Tokyo Medical University, Nishi-Shinjuku, Tokyo, JapanPurpose: We evaluated the 2-year efficacy of combined intravitreal ranibizumab (IVR) treatment and photodynamic therapy (PDT) for treatment-na&iuml;ve polypoidal choroidal vasculopathy (PCV).Patients and methods: Twenty-two eyes of 22 Japanese patients with treatment-na&iuml;ve PCV were prospectively recruited. All eyes had angiographic features of PCV according to indocyanine green angiography. The initial combination treatment regimen included a session of PDT with IVR. A total of three consecutive IVR treatments were given at 4-week intervals. Eyes were retreated with IVR or PDT at specific times. We evaluated the mean visual acuity and mean central retinal thickness (CRT) at 3, 6, 9, 12, 18, and 24 months after initial treatment.Results: At month 9, visual acuity had improved by 5.7 letters (P = 0.10). Subsequently, mean visual acuity gradually decreased, and the difference from baseline was diminished to 2.9 letters at 24 months (P = 0.43). Mean CRT was significantly decreased from baseline over the 24-month follow-up (P &lt; 0.05).Conclusion: With PDT combined with IVR for PCV, visual acuity improved during year 1, but the benefit decreased in year 2.Keywords: photodynamic therapy, polypoidal choroidal vasculopathy, ranibizumab
format	article
author	Nemoto R Miura M Iwasaki T Goto H
author_facet	Nemoto R Miura M Iwasaki T Goto H
author_sort	Nemoto R
title	Two-year follow-up of ranibizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy
title_short	Two-year follow-up of ranibizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy
title_full	Two-year follow-up of ranibizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy
title_fullStr	Two-year follow-up of ranibizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy
title_full_unstemmed	Two-year follow-up of ranibizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy
title_sort	two-year follow-up of ranibizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/5a9a36226e494f9d90526e06c51cd2a6
work_keys_str_mv	AT nemotor twoyearfollowupofranibizumabcombinedwithphotodynamictherapyforpolypoidalchoroidalvasculopathy AT miuram twoyearfollowupofranibizumabcombinedwithphotodynamictherapyforpolypoidalchoroidalvasculopathy AT iwasakit twoyearfollowupofranibizumabcombinedwithphotodynamictherapyforpolypoidalchoroidalvasculopathy AT gotoh twoyearfollowupofranibizumabcombinedwithphotodynamictherapyforpolypoidalchoroidalvasculopathy
_version_	1718398245774819328

Two-year follow-up of ranibizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy

Ejemplares similares